Fig. 5.

HBXIP-elevated PKM2 contributes to accelerated cell proliferation in ER+ breast cancer. a, b Cell viability assay in MCF-7 (a) and T47D (B) cells transiently transfected with indicated plasmids or siRNAs. c, d EdU assay in MCF-7 cells transiently transfected with indicated plasmids or siRNAs. Scale bar, 50 μm. e Interference efficiency of PKM2 siRNAs validated by immunoblotting assay in MCF-7 cells. Statistically significant differences are indicated: **P < 0.01, ***P < 0.001; all experiments were repeated at least three times